|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MFSD4A |
Gene summary for MFSD4A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MFSD4A | Gene ID | 148808 |
| Gene name | major facilitator superfamily domain containing 4A | |
| Gene Alias | MFSD4 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8N468 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 148808 | MFSD4A | HTA11_347_2000001011 | Human | Colorectum | AD | 2.93e-05 | 3.57e-01 | -0.1954 |
| 148808 | MFSD4A | HTA11_411_2000001011 | Human | Colorectum | SER | 5.90e-05 | 8.38e-01 | -0.2602 |
| 148808 | MFSD4A | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.09e-09 | 9.08e-01 | -0.2061 |
| 148808 | MFSD4A | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.23e-04 | 5.55e-01 | 0.3371 |
| 148808 | MFSD4A | RNA-P17T-P17T-6 | Human | Lung | IAC | 2.00e-06 | 6.71e-01 | 0.3385 |
| 148808 | MFSD4A | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.10e-05 | 5.42e-01 | 0.3329 |
| 148808 | MFSD4A | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.15e-07 | 3.32e-01 | -0.0121 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MFSD4A | SNV | Missense_Mutation | novel | c.1383N>T | p.Gln461His | p.Q461H | Q8N468 | protein_coding | tolerated(0.16) | benign(0.332) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| MFSD4A | SNV | Missense_Mutation | rs750941919 | c.962C>T | p.Thr321Met | p.T321M | Q8N468 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MFSD4A | SNV | Missense_Mutation | novel | c.878G>C | p.Ser293Thr | p.S293T | Q8N468 | protein_coding | tolerated(0.06) | possibly_damaging(0.697) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MFSD4A | SNV | Missense_Mutation | c.706G>A | p.Ala236Thr | p.A236T | Q8N468 | protein_coding | tolerated(0.08) | benign(0.422) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| MFSD4A | SNV | Missense_Mutation | novel | c.1370N>C | p.Ile457Thr | p.I457T | Q8N468 | protein_coding | deleterious(0.01) | benign(0.069) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MFSD4A | SNV | Missense_Mutation | novel | c.797N>G | p.Glu266Gly | p.E266G | Q8N468 | protein_coding | deleterious(0.01) | possibly_damaging(0.601) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MFSD4A | SNV | Missense_Mutation | c.1171N>A | p.Leu391Met | p.L391M | Q8N468 | protein_coding | tolerated(0.08) | probably_damaging(0.984) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MFSD4A | SNV | Missense_Mutation | novel | c.311N>G | p.Asp104Gly | p.D104G | Q8N468 | protein_coding | deleterious(0.04) | benign(0.253) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| MFSD4A | SNV | Missense_Mutation | rs556886499 | c.292N>A | p.Val98Ile | p.V98I | Q8N468 | protein_coding | tolerated(1) | benign(0.007) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MFSD4A | SNV | Missense_Mutation | novel | c.1188N>A | p.Phe396Leu | p.F396L | Q8N468 | protein_coding | tolerated(0.34) | benign(0.014) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |